Association and gene–gene interactions study of reelin signaling pathway related genes with autism in the Han Chinese population / Yidong SHEN in Autism Research, 9-4 (April 2016)  

Public ISBD [article]  inAutism Research > 9-4 (April 2016) . - p.436-442 Titre : Association and gene–gene interactions study of reelin signaling pathway related genes with autism in the Han Chinese population Type de document : Texte imprimé et/ou numérique Auteurs : Yidong SHEN, Auteur ; Guanglei XUN, Auteur ; Hui GUO, Auteur ; Yiqun HE, Auteur ; Jianjun OU, Auteur ; Huixi DONG, Auteur ; Kun XIA, Auteur ; Jingping ZHAO, Auteur Article en page(s) : p.436-442 Langues : Anglais (eng) Mots-clés : autism  reelin  signaling pathway  interaction  polymorphism Index. décimale : PER Périodiques Résumé : Autism is a neurodevelopmental disorder with unclear etiology. Reelin had been proposed to participate in the etiology of autism due to its important role in brain development. The goal of this study was to explore the association and gene–gene interactions of reelin signaling pathway related genes (RELN, VLDLR, LRP8, DAB1, FYN, and CDK5) with autism in Han Chinese population. Genotyping data of the six genes were obtained from a recent genome-wide association study performed in 430 autistic children who fulfilled the DSM-IV-TR criteria for autistic disorder, and 1,074 healthy controls. Single marker case-control association analysis and haplotype case-control association analysis were conducted after the data was screened. Multifactor dimensionality reduction (MDR) was applied to further test gene–gene interactions. Neither the single marker nor the haplotype association tests found any significant difference between the autistic group and the control group after permutation test of 1,000 rounds. The 4-locus MDR model (comprising rs6143734, rs1858782, rs634500, and rs1924267 which belong to RELN and DAB1) was determined to be the model with the highest cross-validation consistency (CVC) and testing balanced accuracy. The results indicate that an interaction between RELN and DAB1 may increase the risk of autism in the Han Chinese population. Furthermore, it can also be inferred that the involvement of RELN in the etiology of autism would occur through interaction with DAB1. Autism Res 2016, 9: 436–442. © 2015 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.1540 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=287 [article] Association and gene–gene interactions study of reelin signaling pathway related genes with autism in the Han Chinese population [Texte imprimé et/ou numérique] / Yidong SHEN, Auteur ; Guanglei XUN, Auteur ; Hui GUO, Auteur ; Yiqun HE, Auteur ; Jianjun OU, Auteur ; Huixi DONG, Auteur ; Kun XIA, Auteur ; Jingping ZHAO, Auteur . - p.436-442. Langues : Anglais (eng) in Autism Research > 9-4 (April 2016) . - p.436-442 Mots-clés : autism  reelin  signaling pathway  interaction  polymorphism Index. décimale : PER Périodiques Résumé : Autism is a neurodevelopmental disorder with unclear etiology. Reelin had been proposed to participate in the etiology of autism due to its important role in brain development. The goal of this study was to explore the association and gene–gene interactions of reelin signaling pathway related genes (RELN, VLDLR, LRP8, DAB1, FYN, and CDK5) with autism in Han Chinese population. Genotyping data of the six genes were obtained from a recent genome-wide association study performed in 430 autistic children who fulfilled the DSM-IV-TR criteria for autistic disorder, and 1,074 healthy controls. Single marker case-control association analysis and haplotype case-control association analysis were conducted after the data was screened. Multifactor dimensionality reduction (MDR) was applied to further test gene–gene interactions. Neither the single marker nor the haplotype association tests found any significant difference between the autistic group and the control group after permutation test of 1,000 rounds. The 4-locus MDR model (comprising rs6143734, rs1858782, rs634500, and rs1924267 which belong to RELN and DAB1) was determined to be the model with the highest cross-validation consistency (CVC) and testing balanced accuracy. The results indicate that an interaction between RELN and DAB1 may increase the risk of autism in the Han Chinese population. Furthermore, it can also be inferred that the involvement of RELN in the etiology of autism would occur through interaction with DAB1. Autism Res 2016, 9: 436–442. © 2015 International Society for Autism Research, Wiley Periodicals, Inc. En ligne : http://dx.doi.org/10.1002/aur.1540 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=287

Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial / Robert C. SMITH ; Russell H. TOBE ; Jingjing LIN ; Jen ARRIAZA ; Jed W. FAHEY ; Ruiting LIU ; Ying ZENG ; Yanan LIU ; Lian HUANG ; Yidong SHEN ; Yamin LI ; Daomeng CHENG ; Brian CORNBLATT ; John M. DAVIS ; Jingping ZHAO ; Renrong WU ; Hua JIN in Journal of Autism and Developmental Disorders, 54-2 (February 2024)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 54-2 (February 2024) . - p.628-641 Titre : Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial Type de document : Texte imprimé et/ou numérique Auteurs : Robert C. SMITH, Auteur ; Russell H. TOBE, Auteur ; Jingjing LIN, Auteur ; Jen ARRIAZA, Auteur ; Jed W. FAHEY, Auteur ; Ruiting LIU, Auteur ; Ying ZENG, Auteur ; Yanan LIU, Auteur ; Lian HUANG, Auteur ; Yidong SHEN, Auteur ; Yamin LI, Auteur ; Daomeng CHENG, Auteur ; Brian CORNBLATT, Auteur ; John M. DAVIS, Auteur ; Jingping ZHAO, Auteur ; Renrong WU, Auteur ; Hua JIN, Auteur Article en page(s) : p.628-641 Index. décimale : PER Périodiques Résumé : Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N?=?108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings. En ligne : https://doi.org/10.1007/s10803-022-05784-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=520 [article] Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial [Texte imprimé et/ou numérique] / Robert C. SMITH, Auteur ; Russell H. TOBE, Auteur ; Jingjing LIN, Auteur ; Jen ARRIAZA, Auteur ; Jed W. FAHEY, Auteur ; Ruiting LIU, Auteur ; Ying ZENG, Auteur ; Yanan LIU, Auteur ; Lian HUANG, Auteur ; Yidong SHEN, Auteur ; Yamin LI, Auteur ; Daomeng CHENG, Auteur ; Brian CORNBLATT, Auteur ; John M. DAVIS, Auteur ; Jingping ZHAO, Auteur ; Renrong WU, Auteur ; Hua JIN, Auteur . - p.628-641. in Journal of Autism and Developmental Disorders > 54-2 (February 2024) . - p.628-641 Index. décimale : PER Périodiques Résumé : Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N?=?108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings. En ligne : https://doi.org/10.1007/s10803-022-05784-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=520

---

1 (1 - 2 / 2)